Abstract
Intravenous immunoglobulins (IVIg) are used in treatment of a broad spectrum of diseases. Immunoglobulin replacement therapy is the standard treatment for immunodeficiencies with compromised humoural immunity. Use of this method as an immunomodulating therapy ranges from transplantation and treatment of autoimmune-haematological diseases to treatment of various neuroimmunological clinical entities. Limited quantitative availability due to dependence on human donors as a source of IVIg, coupled with high treatment costs, make necessary a highly responsible and evidence-based approach with these agents.
Discussion of the indications and currently valid recommendations on use of IVIg in treatment of immunomediated demyelinating diseases of the nervous system is based on existing clinical studies.
We describe further neurological indications for use of IVIg as well as mechanisms of action and adverse effects of its use.
Keywords: Intravenous immunoglobulin, treatment, immune-mediated demyelinating diseases, side-effects, multiple sclerosis, humoural immunity, First-line therapy, antibody deficiency syndrome, clinical trials, central nervous system.
Current Pharmaceutical Design
Title:Use of Intravenous Immunoglobulin in the Treatment of Immune-Mediated Demyelinating Diseases of the Nervous System
Volume: 18 Issue: 29
Author(s): Alexander Winkelmann and Uwe K. Zettl
Affiliation:
Keywords: Intravenous immunoglobulin, treatment, immune-mediated demyelinating diseases, side-effects, multiple sclerosis, humoural immunity, First-line therapy, antibody deficiency syndrome, clinical trials, central nervous system.
Abstract: Intravenous immunoglobulins (IVIg) are used in treatment of a broad spectrum of diseases. Immunoglobulin replacement therapy is the standard treatment for immunodeficiencies with compromised humoural immunity. Use of this method as an immunomodulating therapy ranges from transplantation and treatment of autoimmune-haematological diseases to treatment of various neuroimmunological clinical entities. Limited quantitative availability due to dependence on human donors as a source of IVIg, coupled with high treatment costs, make necessary a highly responsible and evidence-based approach with these agents.
Discussion of the indications and currently valid recommendations on use of IVIg in treatment of immunomediated demyelinating diseases of the nervous system is based on existing clinical studies.
We describe further neurological indications for use of IVIg as well as mechanisms of action and adverse effects of its use.
Export Options
About this article
Cite this article as:
Winkelmann Alexander and K. Zettl Uwe, Use of Intravenous Immunoglobulin in the Treatment of Immune-Mediated Demyelinating Diseases of the Nervous System, Current Pharmaceutical Design 2012; 18 (29) . https://dx.doi.org/10.2174/138161212802502314
DOI https://dx.doi.org/10.2174/138161212802502314 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Biomarkers for Lupus Nephritis in the “OMICS” Era
Current Medicinal Chemistry Adverse Cardiovascular Effects of Antirheumatic Drugs: Implications for Clinical Practice and Research
Current Pharmaceutical Design Quantitative Determination and Validation of Four Phenolic Acids in <i>Salvia Miltiorrhiza</i> Bunge using <sup>1</sup>H-NMR Spectroscopy
Current Pharmaceutical Analysis Overlooked Issues of Snakebite Management: Time for Strategic Approach
Current Topics in Medicinal Chemistry Interventional Radiology in Paediatrics
Current Pediatric Reviews Detection and Transport Mechanisms of Circulating microRNAs in Neurological, Cardiac and Kidney Diseases
Current Medicinal Chemistry Substance P and Alzheimer’s Disease: Emerging Novel Roles
Current Alzheimer Research Update on the Principles and Novel Local and Systemic Therapies for the Treatment of Non-Infectious Uveitis
Inflammation & Allergy - Drug Targets (Discontinued) Natural Compounds with Proteasome Inhibitory Activity for Cancer Prevention and Treatment
Current Protein & Peptide Science Impact of Traditional Therapies and Biologics on Cardiovascular Diseases in Rheumatoid Arthritis
Current Vascular Pharmacology Giant Pulmonary Artery Aneurysm Secondary To Patent Ductus Arteriosus: A Case Report
Current Cardiology Reviews Substance P Prevents Vascular Endothelial Dysfunction in Metastatic Breast Carcinoma
Protein & Peptide Letters Treatment of Central Nervous System Tuberculosis Infections and Neurological Complications of Tuberculosis Treatment
Current Pharmaceutical Design Reduction of Hyperproduction of Thyroid Autoantibodies in Patients without Disturbance of the Thyroid Function: New Patents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Pharmacological, Immunological, and Gene Targeting of the Renin-Angiotensin System for Treatment of Cardiovascular Disease
Current Pharmaceutical Design Main Anti-tumor Angiogenesis Agents Isolated From Chinese Herbal Medicines
Mini-Reviews in Medicinal Chemistry Actions of Adjunctive Nutritional Antioxidants in Periodontitis and Prevalent Systemic Inflammatory Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Rheumatoid Foot and Ankle Surgery
Current Rheumatology Reviews A Review of the Treatment of Psoriasis with Infliximab
Reviews on Recent Clinical Trials Von Willebrand Factor and Cardiovascular Disease: From a Biochemical Marker to an Attractive Therapeutic Target
Current Vascular Pharmacology